Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas

Blood

Volumn 128, Issue 11, 2016, Pages 1490-1502

  Vallois, David ^a   Dobay, Maria Pamela D ^b   Morin, Ryan D ^c,d   Lemonnier, François ^e   Missiaglia, Edoardo ^a   Juilland, Mélanie ^f   Iwaszkiewicz, Justyna ^b   Fataccioli, Virginie ^e   Bisig, Bettina ^a   Roberti, Annalisa ^a   Grewal, Jasleen ^c   Bruneau, Julie ^g   Fabiani, Bettina ^h   Martin, Antoine ⁱ   Bonnet, Christophe ^j   Michielin, Olivier ^b,k   Jais, Jean Philippe ^g   Figeac, Martin ^l   Bernard, Olivier A ^m   Delorenzi, Mauro ^b,f,k   Haioun, Corinne ⁿ   Tournilhac, Olivier ^o   Thome, Margot ^f   Gascoyne, Randy D ^d   Gaulard, Philippe ^e   De Leval, Laurence ^a   more..

^a UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^b SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^c SIMON FRASER UNIVERSITY   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ AVICENNE HOSPITAL   (France)

^j UNIVERSITY OF LIÈGE   (Belgium)

^k LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^l Institut Pour la Recherche sur le Cancer de Lille (IRCL)   (France)

^m INSTITUT GUSTAVE ROUSSY   (France)

ⁿ HENRI MONDOR HOSPITAL   (France)

^o UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARD11 PROTEIN; CD28 ANTIGEN; CTNNB1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALT1 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLCG1 PROTEIN; PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; RHOA PROTEIN, HUMAN; TUMOR MARKER;

ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTOMICS; WHOLE EXOME SEQUENCING; CANCER STAGING; COHORT ANALYSIS; FOLLICULAR LYMPHOMA; FOLLOW UP; GENETICS; HELPER CELL; HIGH THROUGHPUT SEQUENCING; IMMUNOBLASTIC LYMPHADENOPATHY; IMMUNOLOGY; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS; T LYMPHOCYTE RECEPTOR GENE;

BIOMARKERS, TUMOR; COHORT STUDIES; FOLLOW-UP STUDIES; GENES, T-CELL RECEPTOR; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOBLASTIC LYMPHADENOPATHY; LYMPHOMA, FOLLICULAR; LYMPHOMA, T-CELL, PERIPHERAL; MUTATION; NEOPLASM STAGING; PROGNOSIS; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84988414113     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-02-698977     Document Type: Article

References (57)

1. Federico M, Rudiger T, Bellei M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31(2):240-246.
2. de Leval L, Parrens M, Le Bras F, et al. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica. 2015;100(9): e361-e364.
3. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952-4963.
4. Gaulard P, de Leval L. Pathology of peripheral T-cell lymphomas: where do we stand? Semin Hematol. 2014;51(1):5-16.
5. Dobay MP, Lemonnier F, Missiaglia E, et al. A PTCL, NOS subset with molecular and clinical features similar to AITL. Hematol Oncol. 2015; 33(S1):100-180.
6. Mourad N, Mounier N, Brière J, et al; Groupe d'Etude des Lymphomes de l'Adulte. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood. 2008;111(9): 4463-4470.
7. Corradini P, Vitolo U, Rambaldi A, et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia. 2014; 28(9):1885-1891.
8. Lemonnier F, Couronné L, Parrens M, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012;120(7): 1466-1469.
9. Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119(8):1901-1903.
10. Jaiswal S, Fontanillas P, Flannick J, et al. Agerelated clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26): 2488-2498.
11. Muto H, Sakata-Yanagimoto M, Nagae G, et al. Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J. 2014;4(12): e264.
12. Palomero T, Couronné L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46(2): 166-170.
13. Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171-175.
14. Yoo HY, Sung MK, Lee SH, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(4):371-375.
15. Cleverley SC, Costello PS, Henning SW, Cantrell DA. Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma. Oncogene. 2000;19(1):13-20.
16. Odejide O, Weigert O, Lane AA, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014;123(9): 1293-1296.
17. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015; 21(8):922-926.
18. Inghirami G, Chan WC, Pileri S; AIRC 5xMille consortium 'Genetics-driven targeted management of lymphoid malignancies'. Peripheral T-cell and NK cell lymphoproliferative disorders: cell of origin, clinical and pathological implications. Immunol Rev. 2015; 263(1):124-159.
19. Pechloff K, Holch J, Ferch U, et al. The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. J Exp Med. 2010;207(5):1031-1044.
20. Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47(11): 1304-1315.
21. Vaqué JP, Gómez-López G, Monsálvez V, et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood. 2014;123(13):2034-2043.
22. Manso R, Rodríguez-Pinilla SM, González-Rincón J, et al. Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas. Haematologica. 2015;100(1):e25-e27.
23. da Silva Almeida AC, Abate F, Khiabanian H, et al. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. Nat Genet. 2015;47(12):1465-1470.
24. Wang L, Ni X, Covington KR, et al. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet. 2015;47(12):1426-1434.
25. Rohr J, Guo S, Huo J, et al. Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. Leukemia. 2016;30(5):1062-1070.
26. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360): 298-303.
27. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319(5870): 1676-1679.
28. Pelzer C, Cabalzar K, Wolf A, Gonzalez M, Lenz G, Thome M. The protease activity of the paracaspase MALT1 is controlled by monoubiquitination. Nat Immunol. 2013;14(4):337-345.
29. Wang D, You Y, Case SM, et al. A requirement for CARMA1 in TCR-induced NF-kappa B activation. Nat Immunol. 2002;3(9):830-835.
30. Lee SH, Kim JS, Kim J, et al. A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients. Haematologica. 2015;100(12):e505-e507.
31. Huang C-H, Mandelker D, Schmidt-Kittler O, et al. The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kalpha mutations. Science. 2007;318(5857): 1744-1748.
32. Austinat M, Dunsch R, Wittekind C, Tannapfel A, Gebhardt R, Gaunitz F. Correlation between β-catenin mutations and expression of Wntsignaling target genes in hepatocellular carcinoma. Mol Cancer. 2008;7(1):21.
33. Pilati C, Letouzé E, Nault J-C, et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell. 2014;25(4):428-441.
34. Stolze B, Reinhart S, Bulllinger L, Fröhling S, Scholl C. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci Rep. 2015;5:8535.
35. Ohgami RS, Ma L, Monabati A, Zehnder JL, Arber DA. STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica. 2014;99(7):e105-e107.
36. Nagata Y, Kontani K, Enami T, et al. Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood. 2016;127(5):596-604.
37. Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20): 1905-1913.
38. Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048-3057.
39. Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2012;2(7): 591-597.
40. Kiel MJ, Velusamy T, Rolland D, et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014;124(9):1460-1472.
41. Bellanger D, Jacquemin V, Chopin M, et al. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. Leukemia. 2014; 28(2):417-419.
42. Nicolae A, Xi L, Pittaluga S, et al. Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas. Leukemia. 2014;28(11):2244-2248.
43. Küçük C, Jiang B, Hu X, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells. Nat Commun. 2015;6:6025.
44. Avbelj M, Wolz O-O, Fekonja O, et al. Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization. Blood. 2014;124(26):3896-3904.
45. Ihara K, Muraguchi S, Kato M, et al. Crystal structure of human RhoA in a dominantly active form complexed with a GTP analogue. J Biol Chem. 1998;273(16):9656-9666.
46. Laham LE, Mukhopadhyay N, Roberts TM. The activation loop in Lck regulates oncogenic potential by inhibiting basal kinase activity and restricting substrate specificity. Oncogene. 2000; 19(35):3961-3970.
47. Chinen Y, Kuroda J, Shimura Y, et al. Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma. Cancer Res. 2014;74(24): 7418-7429.
48. Sacristán C, Schattgen SA, Berg LJ, Bunnell SC, Roy AL, Rosenstein Y. Characterization of a novel interaction between transcription factor TFII-I and the inducible tyrosine kinase in T cells. Eur J Immunol. 2009;39(9): 2584-2595.
49. Petrini I, Meltzer PS, Kim I-K, et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet. 2014;46(8):844-849.
50. Razanadrakoto L, Cormier F, Laurienté V, et al. Mutation of Vav1 adaptor region reveals a new oncogenic activation. Oncotarget. 2015;6(4): 2524-2537.
51. Singh NJ, Schwartz RH. The strength of persistent antigenic stimulation modulates adaptive tolerance in peripheral CD4+ T cells. J Exp Med. 2003;198(7):1107-1117.
52. Ishikawa S. Opposite RHOA functions within the ATLL category. Blood. 2016;127(5):524-525.
53. Kiel MJ, Sahasrabuddhe AA, Rolland DCM, et al. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome. Nat Commun. 2015;6:8470.
54. Wang C, McKeithan TW, Gong Q, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood. 2015;126(15): 1741-1752.
55. Sakata-Yanagimoto M. Multistep tumorigenesis in peripheral T cell lymphoma. Int J Hematol. 2015; 102(5):523-527.
56. Quivoron C, Couronné L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1):25-38.
57. Cheminant M, Bruneau J, Kosmider O, et al. Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma. Br J Haematol. 2015;168(6):913-916.